Imricor Medical Systems (ASX:IMR) submitted its NorthStar 3D Mapping System for FDA clearance.
The regulatory submission is specifically designed to target the high-growth paediatric and adult congenital heart disease customer segments.
The NorthStar system serves as a critical "early commercial" bridge, facilitating the broader adoption of Imricor’s comprehensive electrophysiology platform.
By offering a solution that allows for complex interventional procedures under real-time magnetic resonance guidance, the company is addressing a burgeoning demand for clinical environments that reduce or eliminate ionising radiation.
For paediatric patients and those with lifelong congenital conditions, the shift towards radiation-free imaging is increasingly viewed as a standard-of-care necessity.
Imricor’s leadership highlighted that the submission is a direct response to proactive interest from leading children’s hospitals, which have already begun discussions to integrate the technology.
Beyond the immediate paediatric market, NorthStar’s clearance would allow the company to aggressively market its capabilities, broadening its addressable market and building commercial momentum ahead of its full EP suite rollout.
As an interventional MR company, Imricor’s dual-track strategy of regulatory progress and clinical adoption reinforces its status as a pioneer in radiation-free cardiac interventions.
At the time of reporting, Imricor Medical Systems’ share price was $1.94.